• The approval is based on P-III trial assessing Wynzora Cream vs Taclonex Topical Suspension in 794 patients for the treatment of plaque psoriasis in adults 18 years of age or older
• The study resulted in a PGA treatment of 21.6% vs 14.6%- patients achieved at least a 4-point improvement in the peak pruritus NRS score at @4wks. 60.3% vs 21.4%
• Wynzora is a novel topical solution offering high efficacy- favorable safety and excellent and is filled for MAA application in EU

­ Ref: MC2 Therapeutics | Image: MC2 Therapeutics